| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1120541 | F | Agonist activity at human TLR7 expressed in NF-kappaB-stimulated HEK293 cells assessed as induction of secreted alkaline phosphatase expression by reporter gene assay | Homo sapiens | 18 | cell-based format | Scientific Literature | ||
| 2. | ALA1120542 | F | Agonist activity at human TLR8 expressed in NF-kappaB-stimulated HEK293 cells assessed as induction of secreted alkaline phosphatase expression by reporter gene assay | Homo sapiens | 34 | cell-based format | Scientific Literature | ||
| 3. | ALA1120543 | F | Immunostimulatory activity in human whole blood assessed as induction of IFNalpha release after 12 hrs by ELISA | Homo sapiens | 3 | tissue-based format | Scientific Literature | ||
| 4. | ALA2422227 | B | Agonist activity at TLR8 in human PBMC assessed as increase of MIP1beta level after 12 hrs | Homo sapiens | 3 | single protein format | Scientific Literature | ||
| 5. | ALA2422228 | B | Agonist activity at TLR8 in human PBMC assessed as increase of MIP1alpha level after 12 hrs | Homo sapiens | 3 | single protein format | Scientific Literature | ||
| 6. | ALA2422229 | B | Agonist activity at TLR8 in human PBMC assessed as increase of GRO level after 12 hrs | Homo sapiens | 3 | single protein format | Scientific Literature | ||
| 7. | ALA2422230 | B | Agonist activity at TLR8 in human PBMC assessed as increase of G-CSF level after 12 hrs | Homo sapiens | 3 | single protein format | Scientific Literature | ||
| 8. | ALA3301363 | P | ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5 | 4,197 | small-molecule physicochemical format | AstraZeneca Deposited Data | |||
| 9. | ALA3301365 | A | ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma at 37C for >5hrs. Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound. | Homo sapiens | 1,614 | cell-free format | AstraZeneca Deposited Data | ||
| 10. | ALA3301370 | A | ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736. | Homo sapiens | 1,102 | microsome format | AstraZeneca Deposited Data | ||
| 11. | ALA4321168 | F | Antiparasitic activity against Plasmodium berghei ANKA infected in Laca mouse assessed as parasitemia at 10 ug, ip administered for 4 days measured on day 7 by Giemsa-staining based assay | Plasmodium berghei | 1 | organism-based format | Scientific Literature | ||
| 12. | ALA4321169 | F | Antiparasitic activity against Plasmodium berghei ANKA infected in Laca mouse assessed as reduction in parasitemia at 10 ug, ip administered for 4 days measured on day 9 by Giemsa-staining based assay | Plasmodium berghei | 1 | organism-based format | Scientific Literature | ||
| 13. | ALA4321170 | T | Toxicity in Laca mouse infected with Plasmodium berghei ANKA assessed as body weight loss at 10 ug, ip administered for 4 days | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 14. | ALA4321171 | T | Toxicity in Laca mouse infected with Plasmodium berghei ANKA assessed as death at 10 ug, ip administered for 4 days measured on day 15 | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 15. | ALA4321176 | T | Toxicity in Laca mouse infected with Plasmodium berghei ANKA assessed as death at 10 ug, ip co-treated with chloroquine for 4 days measured on day 30 | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 16. | ALA4321177 | F | Antiparasitic activity against Plasmodium berghei ANKA infected in Laca mouse assessed as parasitemia at 10 ug, ip co-administered with chloroquine for 4 days measured on day 30 by Giemsa-staining based assay | Plasmodium berghei | 1 | organism-based format | Scientific Literature | ||
| 17. | ALA4321178 | F | Antiparasitic activity against Plasmodium berghei ANKA infected in Laca mouse assessed as reduction in parasitemia at 10 ug, ip co-administered with chloroquine for 4 days measured on day 25 by Giemsa-staining based assay | Plasmodium berghei | 1 | organism-based format | Scientific Literature | ||
| 18. | ALA4321179 | F | Antiparasitic activity against Plasmodium berghei ANKA infected in Laca mouse assessed as reduction in parasitemia at 10 ug, ip co-administered with chloroquine for 4 days measured on day 23 by Giemsa-staining based assay | Plasmodium berghei | 1 | organism-based format | Scientific Literature | ||
| 19. | ALA4321180 | F | Antiparasitic activity against Plasmodium berghei ANKA infected in Laca mouse assessed as reduction in CD3+ cell level in brain at 10 ug, ip co-administered with chloroquine for 4 days measured on day 10 by flow cytometry | Plasmodium berghei | 1 | organism-based format | Scientific Literature | ||
| 20. | ALA4321181 | F | Antiparasitic activity against Plasmodium berghei ANKA infected in Laca mouse assessed as reduction in CD3+ cell level in brain at 10 ug, ip administered for 4 days measured on day 10 by flow cytometry | Plasmodium berghei | 1 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!